FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average burden							
hours per response	: 0.5						

Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940																			
1. Name and Address of Reporting Person* THOMAS FRANK E					2. Issuer Name and Ticker or Trading Symbol <u>Larimar Therapeutics</u> , <u>Inc.</u> [LRMR]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
												X Director				10% Ov	· I		
(Last)	`	,	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 05/12/2021										Officer (give title below)			Other (s below)	респу
C/O LARIMAR THERAPEUTICS, INC.					05/12/2021														
THREE BALA PLAZA EAST, SUITE 506																			
(Street)					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
BALA														X	Form f	iled by One	e Repo	orting Perso	n
CYNWY	'D PA	1	19004											Form filed by More than One Reporting Person					
(City)	(St	tate)	(Zip)																
		Tab	le I - Non-I	Derivati	ve Se	curitie	s Ac	cqui	ired, D	isp	osed c	f, or B	enefi	cially	y Owned	i			
1. Title of Security (Instr. 3) 2. Transar Date (Month/Date)					Execution Date			e, Transaction Disposed Code (Instr. 5)			ties Acquired (A) d Of (D) (Instr. 3, 4				es Form ally (D) o Following (I) (II		m: Direct cor Indirect Enstr. 4)	7. Nature of Indirect Beneficial Ownership	
									Code	,	Amount	(A) or (D) Pr		rice	Reported Transaction(s) (Instr. 3 and 4)				Instr. 4)
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
					, can	-				_				-					
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Execution Date, Trans ecurity or Exercise (Month/Day/Year) if any Code				saction of			Exp	Expiration Date (Month/Day/Year) A S U D			7. Title and Amount of Securities Underlying Derivative Securit (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Cod	e V	(A)	(D)	Date Exe	e rcisable	Ex Da	xpiration ate	Title	Amo or Num of Shar	nber					
Stock Option (right to buy)	\$10.34	05/12/2021		A		8,300			(1)	05	/12/2031	Common Stock	8,3	800	\$0	8,300		D	

Explanation of Responses:

1. The Option vests on the earlier of (a) May 12, 2022 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company.

/s/ Jennifer Johansson,

05/17/2021

Attorney-in-fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.